Genitourinary Cancers Symposium

RSS | Login | Register

Circulating Tumor Cells Predict Worse Outcomes in Bladder Cancer Patients

Jody A. Charnow February 04, 2012

SAN FRANCISCO—The presence of circulating tumor cells (CTC) in the peripheral blood of patients with urothelial carcinoma of the bladder (UCB) prior to radical cystecomy are associated with worse disease outcomes, researchers reported here at the annual Genitourinary Cancers Symposium.

Similar Outcomes Found with Open, Robotic Cystectomy

Jody A. Charnow February 04, 2012

SAN FRANCISCO—Researchers who compared open and robotic cystectomy for bladder cancer found no significant difference in key outcomes after a median three years of follow-up, according to study findings presented here at the annual Genitourinary Cancers Symposium.

Never-Married Men Fare Worse After Prostate Cancer Surgery

Jody A. Charnow February 04, 2012

SAN FRANCISCO—Prostate cancer patients who have never been married are more likely to die from their disease following radical prostatectomy (RP) compared with married men, according to study findings presented here at the annual Genitourinary Cancers Symposium.

Very Low Testosterone Hikes Prostate Cancer Recurrence Risk

Jody A. Charnow February 04, 2012

SAN FRANCISCO—Extremely low levels of testosterone in men after they have undergone radical prostatectomy (RP) for intermediate- to high-risk prostate cancer are associated with an elevated risk for biochemical recurrence of the disease, researchers reported here at the annual Genitourinary Cancers Symposium.

Brachytherapy May Be An Option for Men with High-Risk Prostate Cancer

Jody A. Charnow February 04, 2012

SAN FRANCISCO—Brachytherapy may be a treatment option for patients with high-risk prostate cancer (HRPC), according to data presented here at the annual Genitourinary Cancers Symposium.

Prostate Cancer Linked to Heavy Alcohol Intake

Jody A. Charnow February 03, 2012

SAN FRANCISCO—Heavy ethanol intake is associated with an increased risk of prostate cancer (PCa) among low-risk men with at least one prior negative prostate biopsy, investigators reported here at the annual Genitourinary Cancers Symposium. It also is associated with an elevated risk for high-grade PCa.

PSA Testing Rates Unchanged for Elderly Men Despite Task Force Guidelines

Jody A. Charnow February 03, 2012

SAN FRANCISCO—PSA testing rates for men aged 75 years and older did not decline despite a 2008 U.S. Preventive Services Task Force (USPSTF) recommendation against PSA screening for men in this age group, according to study findings presented at the annual Genitourinary Cancers Symposium.

Prostate Cancer Patients Far More Likely to Die from Other Causes

Jody A. Charnow February 03, 2012

SAN FRANCISCO—Elderly men who receive definitive local treatment for prostate cancer (PCa) are much more likely to die from causes other than their cancer, a finding that could inform doctor-patient discussions about treatment for localized PCa, investigators reported here at the annual Genitourinary Cancers Symposium.

Many Metastatic Prostate Cancers Go Untreated

Jody A. Charnow February 03, 2012

SAN FRANCISCO—Many patients with metastatic prostate cancer (PCa) never receive anticancer treatment, and older age, lower income, and lack of private health insurance may be among the reasons, according to data presented here at the annual Genitourinary Cancers Symposium.

Novel Drug Prolongs Survival in Men with Advanced Prostate Cancer

Jody A. Charnow February 03, 2012

SAN FRANCISCO—A novel medication may provide a new standard of care for the treatment of patients with castration-resistant prostate cancer (CRPC) and bone metastases, researchers reported here at the annual Genitourinary Cancers Symposium.

Herbal Product May Be Useful for Recurrent Prostate Cancer

Jody A. Charnow February 02, 2012

SAN FRANCISCO—A combination herbal supplement may benefit men with recurrent prostate cancer (PCa), according to a findings presented here at the annual Genitourinary Cancers Symposium.

First PSA Results Predict Long-Term Prostate Cancer Risk

Jody A. Charnow February 02, 2012

SAN FRANCISCO—PSA levels at the first date of testing may predict a man's long-term risk of prostate cancer and mortality in the general population, Danish investigators reported here at the annual Genitourinary Cancers Symposium.

Eating Rye Bread in Adolescence May Cut Prostate Cancer Risk

Jody A. Charnow February 02, 2012

SAN FRANCISCO—Greater rye bread consumption in adolescence may be associated with a decreased risk of prostate cancer, especially advanced disease, according to findings presented here at the annual Genitourinary Cancers Symposium.

Empiric Antibiotics for Elevated PSA of No Clinical Benefit

Jody A. Charnow February 02, 2012

SAN FRANCISCO—New findings presented here at the annual Genitourinary Cancers Symposium challenge the widespread practice of placing patients on an empiric course of antibiotics for a newly elevated PSA level.

Proton Therapy No Better than IMRT for Prostate Cancer

Jody A. Charnow February 02, 2012

SAN FRANCISCO—Proton therapy is no better than intensity modulated radiotherapy (IMRT) as a treatment for localized prostate cancer, and it is associated with greater gastrointestinal toxicities, researchers reported here at the Genitourinary Cancers Symposium.

Cost of RAPN vs. LPN Probed

John Schieszer April 21, 2011

ORLANDO—Robot-assisted partial nephrectomy (RAPN) has more upfront costs than laparoscopic partial nephrectomy (LPN), but these costs may decrease with time as surgeon and operating room staff experience increase, according to a new study.

Drugs Will Not Replace RCC Surgery

April 18, 2011

ORLANDO—New targeted therapies for locally advanced and metastatic renal cell carcinoma (RCC) have ushered in a new era in systemic therapy, according to Christopher Wood, MD, Professor of Urology at the University of Texas M.D. Anderson Cancer Center in Houston.

Hand-Foot Syndrome May Predict Better Sunitinib Outcomes

John Schieszer February 21, 2011

ORLANDO—Patients with metastatic renal cell carcincoma (RCC) who develop hand-foot syndrome (HFS) while being treated with sunitinib may have better progression-free survival and overall survival than those who do not experience HFS, a recent analysis suggests.

New Drug May Treat Difficult PCa Cases

Jody A. Charnow February 20, 2011

ORLANDO—An investigational drug called abiraterone acetate can prolong survival of men with metastatic castration-resistant prostate cancer (CRPC) whose disease is progressing after receiving docetaxel-based chemotherapy, according to new findings.

Data Support Intermittent Androgen Suppression

Jody A. Charnow February 20, 2011

ORLANDO—Intermittent and continuous androgen suppression are associated with similar overall survival outcomes in men who have PSA progression after radiotherapy for prostate cancer (PCa), according to new data.

Interview with Michael Large, MD: Play

Interview with Johanna E. Torfadottir: Play

Interview with Tanya B. Dorff, MD: Play

Interview with Alexander Small: Play

More

Latest CME Article

Renal & Urology News includes a CME article in every print issue, which will also be available online.

View the latest installment:

An Update on Robotic-Assisted Partial Nephrectomy

Legal Issues

Physician Sued For Failing to Follow Up

A primary care doctor referred a patient with an elevated PSA to a urologist. After a negative prostate biopsy, the doctor did not regularly conduct follow-up PSA testing, and the patient eventually died from prostate cancer.